已致10人死亡100人住院 诺和诺德提示复方仿制司美格鲁肽风险

每日经济新闻
08 Nov 2024

司美格鲁肽制剂的复方仿制药安全问题正在引发关注。本月初,FDA(美国食品药品监督管理局)警告称,今年8月14日,接到一名患者投诉,称在位于加州的Fullerton Wellness工厂分发的一瓶司美格鲁肽制剂中发现了黑色颗粒物。此后,在一次州级检查中发现了该工厂存在的缺陷。此次检查后,该工厂自愿停止了运营。FDA称,这家工厂使用未经消毒的原料生产诺和诺德和礼来等公司减肥药的复合版本,这些药物可能会...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10